This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
ETF Investing Areas to Consider for August
by Sweta Jaiswal, FRM
Let's take a look at some ETF areas that can be good investment options for August.
Sanofi to Buy mRNA Developer: ETFs in Focus
by Sanghamitra Saha
Sanofi has agreed to acquire U.S. biotech company Translate Bio to gain exposure in the mRNA vaccine space.
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Time for Pharma and Healthcare ETFs?
by Sanghamitra Saha
The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales
2 Sector ETFs Hovering Around All-Time Highs
by Sanghamitra Saha
The U.S. economic backdrop and investors' sentiments have remained mixed in recent weeks.
Moderna Soars on Inclusion to S&P 500: ETFs in Focus
by Sanghamitra Saha
Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.
Moderna ETFs to Rise on Positive COVID-19 Vaccine Updates
by Sweta Jaiswal, FRM
Moderna has once again come up with interesting updates about its COVID-19 vaccine.
Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight
by Sweta Jaiswal, FRM
The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.
ETFs to Win as Moderna Seeks COVID-19 Vaccine Nod for Teens
by Sweta Jaiswal, FRM
Moderna (MRNA) is once again in the spotlight with an impressive update relating to mRNA-1273.
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
by Sweta Jaiswal, FRM
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
Novavax Vaccine to Get U.S. Approval? ETFs to Benefit
by Sanghamitra Saha
Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
ETFs to Tap Amgen's Drive for Cancer Deal
by Sweta Killa
Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.
How Will Biotech ETFs React to Q4 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?
by Sweta Jaiswal, FRM
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
by Sweta Killa
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.